The recent update to the EASL clinical practice guidelines for the diagnosis and management of patients with PBC is contributing to a change in perception of the disease and in understanding of how patients with PBC should be managed.

This educational symposium will explore the epidemiology, patient treatment and the emerging therapeutic options and the clinical impact of the new guidelines. We hope you will be able to join us for an interactive and engaging discussion about this evolving therapy area.

Breakfast will be provided.

This event has been organised and funded by Intercept Pharma Nederland BV
Kamperingweg 45d, 2803PE, Gouda (NL)
+31 182 71 50 57
info.benelux@interceptpharma.com

BE-PB-MED-00081 / NOV 2017
CHANGING PERSPECTIVES IN PRIMARY BILIARY CHOLANGITIS (PBC)

07:50 Breakfast served

08:00 Welcome and Introduction

*Professor Frederik Nevens, UZ Leuven*

08:05 Epidemiology of cholestatic liver disease in Belgium

*Professor Christophe Moreno, Erasme Brussels*

08:15 Painting the new treatment landscape: novel and emerging therapies for PBC

*Professor Frederik Nevens*

08:25 Panel discussion/Q&A

*All faculty*

This event has been organised and funded by Intercept Pharma Nederland BV, Kamperingweg 45d, 2803PE, Gouda (NL) +31 182 71 50 57 info.benelux@interceptpharma.com

We inform you that INTERCEPT is the data controller responsible for the processing of your personal data and that your personal data will be processed for the purpose of managing your professional relationship with INTERCEPT. This information is intended for the addressee. You can, at any time and pursuant to the Data Protection Law (Belgium, Law of 8 December 1992) request access to your personal data or request that your personal data be rectified if necessary or object to the processing thereof. If you wish to exercise these rights, or if you no longer wish to receive invitations and/or marketing materials from us, please contact us by sending an email to info.benelux@interceptpharma.com, or by writing to the following address: Kampenringweg 45d, 2803PE Gouda, The Netherlands. More information on how INTERCEPT uses and protects personal data can be found here: https://interceptpharma.com/privacyshield/